DELGOCITINIB

Information current as at: 1 June 2026

PBAC meeting date: July 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Anzupgo®
Form and strength:
  • Cream 20 mg per g, 60 g
Submission sponsor:
LEO PHARMA PTY LTD
Condition/indication:
(therapeutic use)
  • Chronic hand eczema (CHE)
Listing requested:
To consider the sponsor's revised proposal for listing delgocitinib for the treatment of moderate to severe CHE where topical corticosteroids failed to achieve an adequate response or are medically inappropriate. This item was previously recommended by the PBAC at its November 2025 meeting.
Funding program:
PBS General Schedule
Request authority level:
Authority Required (Written)
PBAC Submission type:
New PBS listing (–)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
July 2026 PBAC meeting
Opportunity for consumer comment:
Open 25/03/2026 and close 20/05/2026 (see PBS Website)
3PBAC meeting:
Has not yet occurred
4PBAC outcome published:
Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
1221
Page last updated
31 May 2026
Return to the Medicine Status Listing
v.9.19